About us
From Research to innovation,
from innovation to market,
from market to patients.
RebrAIn is a spin-off of the University Hospital of Bordeaux and the Inria, based in the EU and the US, created by Professor Emmanuel Cuny, Neurosurgeon, and Professor Nejib Zemzemi, Researcher at Inria in Applied Mathematics, after 10 years of academic research and 2 theses.
RebrAIn’s service is a best-in-class, supervised AI-driven solution that streamlines complex, patient-specific neurosurgery by providing faster, simpler, and safer treatment through augmented neuromodulation planning.
RebrAIn at a glance
- Revolutionizing the traditional approach by combining advanced algorithms and best-in-class medical data
- Improve patient outcomes with precision-guided therapies,
- Expand access to cutting-edge neurological care for more patients, more diseases, in more medical centers, by more doctors
- Leveraging SaaS technology to bring clinical excellence
- Neuromodulation market change paradigm from 1% to 10% patient treated
|
|
Executive Team
A motivated team, a solid track record
A team of 10 employees with multidisciplinary and complementary expertise in Clinical practice, Data Science, Software development, Market access, Business and Quality & Regulatory Affairs
Strategic board
Emmanuel Cuny
Co-founder, CMO & Board President
Nejib Zemzemi
Co-founder, CSO & CTO
David Caumartin
CEO
Vincent Pretet
M CAPITAL
Amine Benamoussa
KARISTA
Observer
KARISTA
Scientific board
Dr. Shayan Moosa
UVA Charlottesville
(Elias JW)
Dr Charles Munyon
Charlotte Novant Health
Dr. Lain Hermes González
Clínica Universidad
de Navarra SPAIN
Pr Jean Regis
APHM,
Marseille / FRANCE
Pr John D. Rolston
Brigham & Women’s
Hospital – Boston
Dr Joohi Jimenez-Shahed
Neurologist Mount Sinai New-York
Pr Rees Cosgrove
Brigham and Women’s Hospital Boston
Dr Michael J Kinsman
University of Kansas Hospital,
Kansas City / USA
Pr Ausaf A. Bari
UCLA Brain Research Institute,
Los Angeles / USA
Be part of medical innovation!
Beyond the financial aspect, we are looking for investors who believe in our innovation and its positive impact on the fight against neurodegenerative diseases. Investing in RebrAin means joining its ecosystem and contributing to advances in medicine and patient well-being.
Institutional investors
The “Nouvelle Aquitaine” Region and the European Union are supporting RebrAIn as part of the 2021-2027 ERDF/ESF Operational Programme.
venture capital fund
To find out all about the financial and commercial aspects of the start-up, the technological innovation of the project, the opportunities and the size of the global market, we invite you to contact us to present our strategy.